AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.12.92 nM(Exon 19 deletion EGFR); 11.44 nM(L858R/T790M EGFR）
|Cell lines||PC-9 cells|
|Preparation method||Media changes are carried out every 2-3 days and resistant clones allowed to grow to 80% confluency prior to the cells being trypsinised and reseeded at the original seeding density in media containing twice the concentration of EGFR inhibitor. Dose escalations are continued until a final concentration of 1.5 μM Gefitinib, 1.5 μM Afatinib, 1.5 μM WZ4002 or 160 nM AZD-9291 are achieved.|
|Incubation time||48 h|
|Formulation||1% Polysorbate 80|
|Dosages||7.5 mg/kg and 5 mg/kg|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
|Source||Mol Pharm (2016). Figure 2.AZD-9291|
|Cell Lines||cancer cell lines|
|Concentrations||0.1 - 1 μM|
|Incubation Time||72 h|
|Results||Cells were maintained in the absence or presence of increasing concentrations (0.1 - 1 μM) of osimertinib for 72 h, harvested and processed for immunoblotting as described in Materials and methods.|
|Source||Mol Pharm (2016). Figure 1.AZD-9291|
|Cell Lines||MDR19-HEK293 cells|
|Incubation Time||24 h|
|Results||Osimertinib (10 μM) significantly increased the accumulation of fluorescent calcein, an established substrate of ABCB145 in ABCB1-overexpressing KB-V-1 cells and ABCB1-transfected MDR19-HEK293 cells to the same extent as tariquidar, a known inhibitor of ABCB1|
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
Finlay MR, et al. J Med Chem. 2014 Oct 23;57(20):8249-67. PMID: 25271963.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, et al. Cancer Discov. 2014 Sep;4(9):1046-61. PMID: 24893891.
|Related EGFR/HER2 Products|
Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1，which can be used to treat non-small cell lung cancer.
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.